Entecavir vs Lamivudine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Entecavir

Brand: BARACLUDE

First FDA approval: 2005-03-29

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Lamivudine

Brand: EPIVIR

First FDA approval: 2010-10-04

Lowest NADACAcquisition cost floor across all NDCs

$0.222Per unit

$0.249Per unit

Average NADACAcross all dosage forms and strengths

$2.36Up to $44.19

$1.19Up to $8.87

Generic manufacturersActive ANDA holders — FDA Orange Book

816 total ANDAs filed

1020 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$44.1MFull year

$8.4MFull year

Part D claims (CY24)Total fills, all strengths

210K51K beneficiaries

55K11K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$210Per claim, all NDCs

$152Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

8Minimal friction

1Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

52Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes8 manufacturers

Yes10 manufacturers